The targeted therapy everolimus may be safely combined with R - CHOP for new, untreated diffuse large B -
cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology.
Not exact matches
Classified as either Hodgkin
lymphoma or non-Hodgkin
lymphoma, depending on which
cells are affected,
lymphoma accounted for approximately five percent of all new cancers diagnosed in the United States in 2014,
according to the National Cancer Institute.
Administration of chemotherapy to patients hospitalized with diffuse large B
cell lymphoma (DLBCL) was associated with lower odds of death during hospitalization,
according to the results of a study published in Cancer Epidemiology.
Progression - free survival and overall survival curves of patients with peripheral T -
cell lymphoma not otherwise specified
according to histone modifier gene mutations.
A combination of complementary immunotherapy drugs brentuximab vedotin (Adcetris ®) and nivolumab (Opdivo ®) destroyed most cancer
cells in 64 percent of patients with recurrent Hodgkin
lymphoma, according to the results of an early - phase clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the Clinical Lymphoma
lymphoma,
according to the results of an early - phase clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the Clinical
Lymphoma Lymphoma Program.